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Abstract 
Anti-N-Methyl-D-aspartate receptor (NMDAR) encephalitis is a severe 
neuropsychiatric disorder that associates with prominent memory and behavioral 
deficits. Patients’ antibodies react with the N-terminal domain of the GluN1 subunit of 
NMDAR causing in cultured neurons a selective and reversible internalization of cell-
surface receptors. These effects and the frequent response to immunotherapy have 
suggested an antibody-mediated pathogenesis, but to date there is no animal model 
showing that patients’ antibodies cause memory and behavioral deficits. To develop 
such a model, C57BL6/J mice underwent placement of ventricular catheters connected 
to osmotic pumps that delivered a continuous infusion of patients’ or control 
cerebrospinal fluid (CSF, flow rate 0.25 µl/hour, 14 days). During and after the infusion 
period standardized tests were applied, including tasks to assess memory (novel object 
recognition in open field and V-maze paradigms), anhedonic behaviors (sucrose 
preference test), depressive-like behaviors (tail suspension, forced swimming tests), 
anxiety (black and white, elevated plus maze tests), aggressiveness (resident-intruder 
test), and locomotor activity (horizontal and vertical). Animals sacrificed at days 5, 13, 
18, 26 and 46 were examined for brain-bound antibodies and the antibody effects on 
total and synaptic NMDAR clusters and protein concentration using confocal 
microscopy and immunoblot analysis. These experiments showed that animals infused 
with patients’ CSF, but not control CSF, developed progressive memory deficits, and 
anhedonic and depressive-like behaviors, without affecting other behavioral or 
locomotor tasks.  Memory deficits gradually worsened until day 18 (four days after the 
infusion stopped) and all symptoms resolved over the next week. Accompanying brain 
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tissue studies showed progressive increase of brain-bound human antibodies, 
predominantly in the hippocampus (maximal on days 13-18), that after acid-extraction 
and characterization with GluN1-expressing human embryonic kidney (HEK) cells were 
confirmed to be against the NMDAR. Confocal microscopy and immunoblot analysis of 
the hippocampus showed progressive decrease of the density of total and synaptic 
NMDAR clusters and total NMDAR protein concentration (maximal on day 18), 
without affecting the post-synaptic density protein (PSD)95 and α-Amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPAR). These effects occurred in 
parallel with memory and other behavioral deficits and gradually improved after day 18, 
with reversibility of symptoms accompanied by a decrease of brain-bound antibodies 
and restoration of NMDAR levels. Overall, these findings establish a link between 
memory and behavioral deficits and antibody-mediated reduction of NMDAR, provide 
the biological basis by which removal of antibodies and antibody-producing cells 
improve neurological function, and offer a model for testing experimental therapies in 
this and similar disorders.  
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Introduction 
Memory, learning, and behavior depend on the proper function of the excitatory 
glutamate N-Methyl-D-aspartate receptor (NMDAR) and α-Amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) and underlying mechanisms of 
synaptic plasticity (Lau and Zukin 2007; Shepherd and Huganir 2007). The critical role 
of NMDAR in these functions has been shown in animal models in which the NMDAR 
are altered genetically (Mohn et al. 1999; Belforte et al. 2010) or pharmacologically 
(Jentsch and Roth 1999; Mouri et al. 2007). In humans this evidence comes from more 
indirect observations such as studies investigating the effects of phencyclidine or 
ketamine (noncompetitive antagonists of NMDAR that cause psychosis) (Weiner et al. 
2000; Gunduz-Bruce 2009), and brain tissue studies of patients with schizophrenia or 
Alzheimer’s disease in which several molecular pathways that modulate glutamate 
receptor trafficking or function are affected (Hahn et al. 2006; Snyder et al. 2005). In 
2007 we identified a novel disorder (anti-NMDAR encephalitis) that occurs with highly 
specific antibodies against extracellular epitopes located at the amino terminal domain 
of the GluN1 subunit of NMDAR (Dalmau et al. 2007; Gleichman et al. 2012). The 
resulting syndrome resembles the spectrum of symptoms that occurs in genetic or 
pharmacologic models of NMDAR hypofunction, including memory loss and 
neuropsychiatric alterations ranging from psychosis to coma (Dalmau et al. 2008; 
Viaccoz et al. 2014; Irani et al. 2010). Regardless of the type of presentation, most 
patients develop severe problems forming new memories and amnesia of the disease. 
Symptoms are usually accompanied by systemic and intrathecal synthesis of antibodies, 
the latter likely produced by plasma cells contained in brain inflammatory infiltrates 
(Dalmau et al. 2008; Martinez-Hernandez et al. 2011).  These long-lived plasma cells 
and persistent antibody synthesis may explain the lengthy symptoms of most patients 
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(average hospitalization ~3 months) (Dalmau et al. 2008). Yet, despite the severity and 
duration of the disease, 80% of the patients have substantial recovery after 
immunotherapy (accompanied by removal of an underlying tumor, usually an ovarian 
teratoma, when appropriate), or sometimes spontaneously (Titulaer et al. 2013; Iizuka et 
al. 2008).    
Investigations on the potential pathogenic role of patients’ antibodies using 
cultured neurons showed that the antibodies caused crosslinking and selective 
internalization of NMDARs that correlated with the antibody titers, and these effects 
were reversible after removing the antibodies (Hughes et al. 2010; Mikasova et al. 
2012). In contrast, patients’ antibodies did not alter the localization or expression of 
other synaptic proteins, number of synapses, dendritic spines, dendritic complexity, or 
cell survival (Hughes et al. 2010). In parallel experiments, the density of NMDAR was 
also significantly reduced in the hippocampus of rats infused with patients’ antibodies, a 
finding comparable to that observed in the hippocampus of autopsied patients (Hughes 
et al. 2010). Overall, these studies suggested an antibody-mediated pathogenesis, but 
the demonstration that patients’ antibodies caused symptoms remained pending. 
Modeling symptoms and showing that these correlate with antibody-mediated reduction 
of NMDAR would prove the pathogenicity of patients’ antibodies, support the use of 
treatments directed toward decreasing the levels of antibodies or antibody-producing 
cells, and help to investigate experimental therapies in this and similar disorders. We 
report here such a model using continuous 14-day cerebroventricular infusion of 
patients’ CSF in mice. The aims were to determine 1) if patients’ antibodies altered 
memory and behavior, 2) whether mice symptoms correlated with brain antibody-
binding and reduction of NMDAR, and 3) whether the clinical and molecular alterations 
recovered after stopping the antibody infusion. 
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Methods 
Animals 
Male C57BL6/J mice (Charles River), 8-10 weeks old (25-30 g) were housed in cages 
of 5 until one week before surgery when they were housed individually. The room was 
maintained at a controlled temperature (21±1ºC) and humidity (55±10%) with 
illumination at 12 hour cycles; food and water were available ad libitum. All 
experiments were performed during the light phase, and animals were habituated to the 
experimental room for 1 week before starting the tests. All procedures were conducted 
in accordance with standard ethical guidelines (European Communities Directive 
86/609/EU) and approved by the local ethical committees: Comitè Ètic 
d’Experimentació Animal, Institut Municipal d’Assistència Sanitària (Universitat 
Pompeu Fabra), and Instituional Animal Care and Use Committee (University of 
Pennsylvania). 
 
Patients´ CSF samples 
CSF from 25 patients with high titer NMDAR antibodies (all >1:320) were pooled and 
used for cerebroventricular infusion. CSF from 25 subjects without NMDAR antibodies 
(11 with normal pressure hydrocephalus and 14 with non-inflammatory CNS disorders) 
were similarly pooled and used as controls. Before loading the osmotic pumps 
(discussed below), the pooled CSF samples from patients and controls were dialyzed 
(Slide-A-Lyzer 7K, Thermo) against sterile phosphate buffered saline (PBS) overnight 
at 4°C, and the concentration of total IgG normalized to the CSF physiologic 
concentration of 2 mg/dL. All mice received the same pooled CSF either from patients 
or controls. Studies were approved by the institutional review board of Hospital Clínic 
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and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat 
de Barcelona. 
 
Surgery, placement of ventricular catheters and osmotic pumps 
Cerebroventricular infusion of CSF was performed using osmotic pumps (model 1002, 
Alzet, Cupertino, CA) with the following characteristics: volume 100 µl, flow rate 0.25 
µl/hr, and duration 14 days. Twenty-four hours before surgery, two osmotic pumps per 
animal were each loaded with 100 µl of patients’ or control CSF. The pumps were then 
connected to a 0.28 mm IM (internal diameter) polyethylene tube (C314CT, 
PlasticsOne) and left overnight in sterile phosphate buffered saline (PBS) at 37°C. The 
next day, mice were deeply anesthetized by intraperitoneal injection of a mixture of 
ketamine (100 mg per kg) and xylazine (10 mg per kg) along with subcutaneous 
administration of the analgesic meloxicam (1 mg per kg). Mice were then placed in a 
stereotaxic frame, and a bilateral catheter (PlasticsOne, model 3280PD-2.0/SP) was 
inserted into the ventricles (0.02 mm anterior and 1.00 mm lateral from bregma, depth 
0.22 mm) and secured with dental cement. Each arm of the catheter was connected to 
one osmotic pump, which were subcutaneously implanted on the back of the mice. 
Appropriate ventricular placement of the catheters was assessed in randomly selected 
mice injecting methylene blue through the catheters (Figure 1A-C). 
 
Cognitive tasks 
All behavioral tasks were performed by researchers blinded to experimental conditions 
using standardized tests reported by us (Aso et al. 2008; Berrendero et al. 2005; Bura et 
al. 2013; Bura et al. 2007; Bura et al. 2010; Burokas et al. 2012; Filliol et al. 2000; 
Llorente-Berzal et al. 2013; Maldonado et al. 1970; Puighermanal et al. 2009) and 
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others (Taglialatela et al. 2009; Steru et al. 1985; Strekalova et al. 2006; Caille et al. 
1999; Crawley and Goodwin 1980; Konig et al. 1996; Porsolt et al. 1977; Ennaceur 
2010; Handley and Mithani 1984) and following the schedule summarized in Figure 1D. 
The tasks were aimed to assess memory (novel object recognition in open field and V-
maze), anhedonic behaviors (sucrose preference test), depressive-like behaviors (tail 
suspension, and forced swimming tests), anxiety (black and white and elevated plus 
maze tests), aggressiveness (resident-intruder test) and locomotor activity (horizontal 
and vertical activity assessment). A brief description of each task is shown in 
supplemental material. 
 
Brain tissue processing 
To determine the effects of patients’ antibodies on mouse brain, animals were sacrificed 
at the indicated time points (Figure 1D, Days 5, 13, 18, 26 and 46) with CO2. Brains 
were harvested, sagittally split, and transferred to ice-cold PBS. Half of the brain was 
fixed by immersion in 4% paraformaldehyde (PFA) for 1 hour at 4°C, cryoprotected 
with 40% sucrose for 48 hours at 4°C, embedded with freezing media, and snap frozen 
with isopentane chilled with liquid nitrogen. The other half brain was used for 
dissection of hippocampus and cerebellum for IgG and protein extraction (see below).  
 
Immunohistochemistry and quantitative peroxidase staining 
For determination of antibodies bound to brain tissue using immunoperoxidase staining, 
7 µm-thick tissue sections were sequentially incubated with 0.25% H2O2 for 10 minutes 
at 4°C, 5% goat serum for 15 minutes at room temperature (RT), biotinylated goat anti-
human IgG (1:2000, Vector labs, Burlingame, CA, USA) overnight at 4°C, and the 
reactivity developed using avidin-biotin-peroxidase and diaminobenzidine. Sections 
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were mildly counterstained with hematoxylin, and results photographed under a Leica 
DMD108 microscope (Mannheim, Germany). Images were prepared creating a mask for 
diaminobenzidine color, converting the mask to grey scale intensities, and inverting the 
pixels using Adobe Photoshop CS6 package.  Hippocampal, frontal cortex, striatum and 
cerebellar regions were manually outlined; intensity and area were quantified in two 
serial sections using the public domain Fiji ImageJ software (http://fiji.sc/Fiji). Values 
were divided by area and normalized to the group with the highest mean (defined as 
100%, patients’ CSF treated animals sacrificed at day 18). 
 
Immunofluorescence and confocal microscopy with brain tissue  
For determination of antibodies bound to brain tissue using immunofluorescence, 5 µm-
thick tissue sections were blocked with 5% goat serum and 1% bovine serum albumin 
(BSA) for 60 minutes at RT, and incubated overnight at 4°C with Alexa Fluor 488 goat 
anti-human IgG (A11013, diluted 1:1000, Molecular Probes/ Life Technologies, 
Carlsbad, CA, USA). Slides were then mounted with ProlonGold (P36930, Molecular 
Probes) and results scanned under a LSM710 Zeiss confocal microscope. Sections from 
all animals were analyzed in parallel. Quantification of fluorescent intensity in areas of 
CA1, CA3 and DG was done using Fiji ImageJ software. Background was subtracted 
and intensity divided by area. Mean intensity of IgG immunostaining in animals treated 
with patients’ CSF and sacrificed at day 18 was defined as 100%.  
To determine the effects of patients’ antibodies on total and synaptic NMDAR 
clusters and PSD95, non-permeabilized 5 µm-thick sections were blocked with 5% goat 
serum and 1% BSA as above, incubated with human CSF antibodies for 2 hours at RT, 
washed with PBS, permeabilized with Triton 0.3% for 10 minutes at RT, and incubated 
with rabbit polyclonal antibody against PSD95 (diluted 1:250, Clone 18258 Abcam, 
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Cambridge, UK) overnight at 4°C. Next day, the slides were washed and incubated with 
the corresponding secondary antibodies, Alexa Fluor 594 goat anti-human IgG and 
Alexa Fluor 488 goat anti-rabbit IgG (A-11014, A-11008, both diluted 1:1000, 
Molecular Probes) for 1 hour at RT. Slides were mounted as above and results scanned 
with a confocal microscope (Zeiss LSM710) with EC-Plan NEOFLUAR CS 100x/1.3 
NA oil objective. Standardized z-stacks including 50 optical images were acquired from 
five different, equally spaced areas of CA1, CA3, and dentate gyrus (DG) of 
hippocampus using sequential scanning, 1024×1024 lateral resolution, and Nyquist 
optimized z sampling frequency. Images were deconvolved with 20 iterations using 
theoretical point spread functions and maximum likelihood estimation algorithms of 
Huygens Essential software (Scientific Volume Imaging BV, Hilversum, the 
Netherlands). For cluster density analysis a spot detection algorithm from Imaris suite 
7.6.4 (Bitplane, Zurich, Switzerland) was used based on automatic segmentation of the 
images to spots (Banovic et al. 2010). Density of clusters was expressed as spots/µm3. 
Three-dimensional colocalization of clusters (e.g. NMDAR and PSD95) was done using 
a spot-colocalization algorithm implemented in Imaris suite 7.6.4. Synaptic localization 
was defined as colocalization of NMDAR or AMPAR with postsynaptic PSD95. 
Synaptic cluster density was expressed as colocalized spots/µm3. For each animal, five 
identical image stacks in each hippocampal area (CA1, CA2 and DG) were acquired and 
the mean densities calculated for total and synaptic NMDAR and AMPAR. Densities 
were normalized to the mean density of control CSF treated animals (100%). Antibodies 
used were guinea pig GluA1 antibody (1:100, clone AGP-009, Alomone, Jerusalem, 
Israel), and as secondary antibody Alexa Fluor 594 goat anti-guinea pig IgG (A11076, 
1:1000, Molecular Probes).  
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The presence of apoptosis, cellular infiltrates, and complement was assessed in 
the hippocampal region (CA3) in mice sacrificed on day 18 and corresponding controls. 
Apoptosis was determined by standard terminal deoxynucleotidyl transferase mediated 
biotinylated UTP nick end labeling (TUNEL) using the TACS 2TdT-Fluor in situ 
apoptosis detection kit (Trevigen, Gaithersburg, MD, USA), and immunolabeling of 
cleaved caspase 3 (1:200, #9661 Cell Signalling, Technologies, Danvers, MA, USA) 
using a goat anti rabbit – Alexa 488 as secondary antibody (1:1000 Molecular Probes). 
The presence of complement was assessed using rabbit anti-mouse C5b-9 (1:500, 
Abcam) and Alexa Fluor 488 goat anti-rabbit IgG (1:500, #A11008, Molecular Probes). 
Immunolabeling for B- and T lymphocytes was done using rabbit anti-mouse CD3 
(1:1000, #ab16669 Abcam) followed by secondary antibody goat anti-rabbit Alexa 
Fluor 488 (1:1000, Molecular Probes), and rat anti-CD45R (1/10000, #ab64100) 
followed by goat anti-rat Alexa Fluor 594 (1/1000, #A-11007 Molecular Probes). 
Results were scanned with a confocal microscope Zeiss LSM710. 
  
Extraction of human IgG bound to mice brain 
Under a dissection microscope (Zeiss stereomicroscope, Stemi 2000), the hippocampus 
and cerebellum were isolated, weighed, snap frozen, and stored at -80°C. Tissue (10 
mg) was homogenized in 0.5 ml ice-cold PBS with protease inhibitors (Sigma-Aldrich, 
St. Louis, MO, USA) and centrifuged at 16.000g for 5 minutes. All steps were 
performed at 4°C. Washing was repeated four times to remove unbound IgG. The last 
wash was done in 100µl and the supernatant saved as pre-extraction fraction. To extract 
the specifically bound antibodies, the pellet was solubilized for 5 minutes in acid (86µl 
0.1M Na-citrate buffer pH2.7), centrifuged at 16.000g for 5 minutes, and the 
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supernatant neutralized with 14µl 1.5M Tris pH8.8, and used to determine the presence 
of NMDAR (GluN1) antibodies (see below). 
 
Immunofluorescence with HEK293 cells expressing GluN1  
The presence of GluN1 antibodies in IgG extracts from brain was determined using a 
HEK293 cell-based assay expressing GluN1, as reported (Dalmau et al. 2008). After 
fixation with 4% PFA and permeabilization with 0.3% Triton X-100, cells were blocked 
with 1% BSA for 90 minutes, and incubated with undiluted acid-extracted IgG or pre-
extraction fraction from brain of infused mice, at 4°C overnight. The next day, cells 
were washed and incubated with a mouse monoclonal antibody against a non-competing 
GluN1 epitope located at amino acid 660-811 (1:20.000; clone MAB363, Millipore) for 
1 hour at RT, followed by the corresponding Alexa Fluor secondary antibodies 
(A11013, A11032, both diluted 1:1000, Molecular Probes) for 1 hour at RT.  The titer 
of positive samples was calculated by serial dilutions until the reactivity was no longer 
visible. Results were photographed under a fluorescence microscope using Zeiss 
Axiovision software. 
 
Immunoblot analyses 
Total protein from hippocampus and cerebellum was obtained by dissecting these 
regions from 20 µm-thick PFA-fixed sagittal mouse brain sections on glass slides at 4°C 
under a Zeiss stereomicroscope (Stemi 2000). Two consecutive sections of isolated 
hippocampus or cerebellum were then transferred to an Eppendorf tube in PBS 
supplemented with protease inhibitors. Loading buffer (RotiLoad, Roth, Karlsruhe, 
Germany) was added, the solubilized tissue boiled for 5 minutes, and the proteins 
separated in a 10% SDS gel electrophoresis with semi-dry blotting on PVDF 
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membranes. Membranes were blocked in 5% non-fat skim milk and incubated overnight 
at 4°C with the following polyclonal rabbit antibodies: GluN1 (1:1000, Sigma-Aldrich), 
GluR2/3 (1:1000, Abcam), and PSD95 (1:1000, Synaptic Systems, Goettingen, 
Germany), or a monoclonal mouse anti-β-actin (1:20.000, Sigma-Aldrich). Membranes 
were incubated with secondary antibodies for 1 hour at RT (anti-rabbit-IgG-HRP 
1:1000, anti-mouse-IgG-HRP 1:10.000) and analyzed by enhanced chemiluminescence 
(all Amersham-GE Healthcare, Pittsburgh, PA, USA) on a LAS4000 (GE Healthcare, 
Pittsburgh, PA, USA). All studies were done in duplicate. Analyzed films were in the 
linear range of exposure, digitally scanned, and signals quantified using Fiji ImageJ 
software. The signal intensity of each antigen was normalized to that of actin in the 
same lane. The mean intensity of signal in control CSF treated animals was defined as 
100% and all other intensities expressed in percent relative to this value.  
 
Statistics 
Behavioral tests were analyzed using repeated measures two-way ANOVA for tests 
with multiple time points (novel object recognition, sucrose preference test, resident-
intruder test, locomotor activity), independent sample-t tests for tests with single time-
points (forced swimming test, black and white test, elevated plus maze test) or by Mann 
Whitney U for skewed distributions (tail suspension test). Non-normally distributed 
parameters were log-transformed (black and white test, elevated plus maze test). 
Significance of NMDAR antibody titer in acid-extracted IgG fractions was calculated 
using the Kruskal-Wallis test and Dunn's post-hoc test compared to titers at day 46. 
Human IgG intensity, confocal cluster density and immunoblot data (GluN1/PSD95) 
from different time points or regions were analyzed using two-way ANOVA with 
Sidak-Holm post-hoc testing to calculate multiplicity-adjusted p-values. Confocal 
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cluster density in the different hippocampal subregions (CA1, CA3, DG) were not 
significantly different and were analyzed pooled.  All experiments were assessed 
visually for outliers (e.g., one animal with very different results from the other animals 
at the same time point), but none were identified, so measurements were pooled per 
time point and treatment (patient or control CSF). For confocal AMPAR cluster density 
measured at single time points, independent sample-t tests were used. A p-value of < 
0.05 was considered significant in post-hoc testing after correction for multiple testing 
(Sidak-Holm). In the two-way ANOVA the cut-off for interaction between 2 factors 
was set at 0.10; if the p-value for interaction was < 0.10, the effects of treatment were 
considered for the separate time points (post-hoc analysis). All tests were done using 
GraphPad Prism (Version 6, La Jolla, CA, USA). 
 
Results 
One-hundred and eleven mice were included in the studies, 56 for cognitive and 
behavioral tests, and 55 for assessment of antibody binding to brain and the effects on 
total and synaptic NMDAR (Figure 1). 
Cerebroventricular infusion of patients’ CSF alters memory and behavior in mice 
The most robust effect during the 14-day infusion of patients’ CSF was on the novel 
object recognition test in both the open field and V-maze paradigms (Figure 2A,B). 
Compared with animals infused with control CSF, those infused with patients’ CSF 
showed a progressive decrease of the object recognition index, indicative of a memory 
deficit (Bura et al 2007; Taglialatela et al. 2009; Puighermanal et al. 2009). The 
memory deficit became significant on day 10 and was maximal on day 18 (four days 
after the infusion of CSF had stopped). On day 25, the object recognition index had 
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normalized and was similar to that of animals treated with control CSF (Figure 2A,B). 
For all time-points, the total time spent exploring both objects (internal control) was 
similar in animals infused with control or patients’ CSF (Supplemental Table 1).  
The preference to drink sweetened water (sucrose preference test) was used as a 
measure of anhedonic behavior. Mice infused with patients’ CSF and tested during the 
infusion period (day 10) had less preference for sucrose compared with mice infused 
with control CSF (Figure 2C). In contrast, the same mice tested 10 days after the 
infusion of CSF had stopped (day 24) showed a preference for sucrose similar to that of 
the control mice. The total consumption of water with and without sucrose was similar 
in both groups (internal control, Supplemental Table 1). In addition, two tests of 
depressive-like behavior were performed. The tail-suspension test, performed on day 
12, showed that animals infused with patients’ CSF had longer periods of immobility 
compared with those infused with control CSF (Figure 2D). In contrast, six days after 
the infusion of CSF had stopped (day 20), no differences were noted with the forced 
swimming test (examining immobility in inescapable situations; Figure 2E, 
Supplemental Table 1).  Overall, these findings suggest that the infusion of NMDAR 
antibodies was associated with anhedonic and depressive-like behaviors.  
In contrast to the prominent memory deficit, along with anhedonia and 
depressive behavior, no significant differences were noted in tests of anxiety (black and 
white test, elevated plus maze test), aggression (resident-intruder test) and locomotor 
activity (Figure 3A-D). 
 
Patients’ antibodies bind to NMDAR in mouse brain  
Animals infused with patients’ CSF, but not control CSF, had progressively increasing 
human IgG immunostaining (representing IgG bound to brain) that correlated with the 
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duration of the infusion. The distribution of IgG immunostaining predominated in 
regions with high density of NMDAR, mainly the hippocampus (Figure 4A), 
resembling that obtained with brain sections directly incubated with patients’ CSF or a 
monoclonal antibody against GluN1 (Dalmau et al. 2008). Upon quantification of 
immunostaining, the maximal antibody binding was identified in mice sacrificed on day 
18, which had received 14 days of CSF infusion, compared with mice sacrificed on days 
5 or 13 (Figure 4B,C). In animals sacrificed on days 26 and 46 the presence of IgG 
immunostaining progressively decreased. In frontal cortex the dynamics of IgG binding 
were similar to those of the hippocampus (Supplemental Figure 1), but the amount of 
IgG was substantially less; in other brain regions such as the cerebellum and striatum, 
the IgG immunostaining was sparse and not significantly different between animals 
infused with patients’ CSF or control CSF (data not shown).   
Studies with immunofluorescence and confocal microscopy showed that in 
animals infused with patients’ CSF the presence of hippocampal IgG was visible as a 
punctate immunolabeling on the surface of neurons and neuronal processes in contrast 
to mice infused with control CSF where minor amounts of IgG reactivity without 
preference for neuronal structures were noted (Figure 4D-G).  In addition, the amount of 
human IgG bound to all selected regions of hippocampus was significantly higher than 
in the control group (Figure 4H). 
To determine if the IgG immunostaining represented brain-bound NMDAR 
antibodies, IgG was extracted from several brain regions and examined for reactivity 
with HEK cells expressing GluN1. These studies showed that the IgG extracted from 
hippocampus of mice infused with patients’ CSF reacted specifically with GluN1 
(Figure 5A). The NMDAR antibody concentration in the extracts correlated with the 
duration of infusion of CSF; it increased until day 13, reached the maximal 
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concentration on days 13-18, and decreased afterwards (Figure 5A,C). NMDAR 
antibodies were also detected in IgG extracts from other brain regions (frontal cortex, 
cerebellum) but at lower concentration to that obtained from hippocampus (Figure 5D). 
Demonstration that the extracted antibodies were specifically bound to the NMDAR 
was provided by the lack of GluN1 reactivity in the pre-extraction fractions (Figure 
5B,E). Parallel studies with tissue from animals infused with control CSF did not show 
NMDAR antibodies (Supplemental Figure 2).  
 
Patients’ antibodies cause a decrease of the density of NMDAR clusters and total 
NMDAR protein in mice hippocampus  
To determine the effects of patients’ antibodies on NMDAR, we focused on the 
hippocampus, which was the region with maximal concentration of NMDAR-bound 
antibodies. Compared with animals infused with control CSF those infused with patients 
CSF had on days 13 and 18 a significant decrease of the density of total and synaptic 
hippocampal NMDAR clusters followed by a gradual recovery after day 18 (pooled 
analysis of CA1, CA3 and DG, Figure 6A-D). No significant differences in between 
hippocampal subregions (CA1, CA3, DG) were observed (not shown). In contrast, 
patients’ antibodies did not alter the density of PSD95 or AMPAR clusters (Figure 
6E,F).  
 Immunoblot analysis of total protein extracted from hippocampus showed that 
on day 13 and 18, mice infused with patients’ CSF had a significant decrease of total 
NMDAR protein concentration compared with mice infused with control CSF (Figure 
7A,B). The magnitude of this effect was greater in animals with higher concentration of 
IgG bound to hippocampus (Figure 7C). Parallel studies examining the effect on the 
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protein concentrations of PSD95 (Figure 7A,E) and AMPAR (Figure 7D) demonstrated 
no significant differences between mice infused with patients’ CSF or control CSF.  
In cerebellum, no significant effects on the cluster density or total protein 
concentration of NMDAR, PSD95 and AMPAR were noted in animals infused with 
patients’ CSF compared to those infused with control CSF (data not shown).    
Immunohistochemical studies for neuronal apoptosis, infiltrates of T- or B-cells, 
and deposits of complement in hippocampus of animals infused with patients’ or control 
CSF, examined on day 18, showed no abnormalities (Figure 8). 
 
Discussion 
We report that passive transfer of NMDAR antibodies by continuous ventricular 
infusion of CSF from patients with anti-NMDAR encephalitis causes memory and 
behavioral deficits in mice, and that the effects are likely mediated by the binding of 
antibodies to NMDAR resulting in a specific decrease of the density of these receptors.  
Data from earlier reports showing that despite the severity and duration of symptoms 
most patients with anti-NMDAR encephalitis respond to immunotherapy (Gresa-Arribas 
et al. 2013), and findings at the cellular level demonstrating that patients’ antibodies 
cause a titer-dependent decrease of synaptic NMDAR receptors fulfilled most of the 
Witebsky’s criteria for an antibody-mediated disease (Rose and Bona 1993), but the 
transfer of symptoms to animals was pending. In the current study, four sets of 
experiments satisfy this postulate, 1) the development of symptoms in animals infused 
with patients’ CSF, but not control CSF, 2) the demonstration that the infused 
antibodies reacted predominantly with brain regions with high density of NMDAR (e.g., 
hippocampus) and specifically recognized these receptors, 3) the identification of a 
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selective decrease of the density of total and synaptic NMDAR clusters and total 
NMDAR protein concentration without affecting PSD95, and that these effects 
correlated with the concentration of brain-bound antibodies, and 4) the correlation noted 
between the intensity of the above-mentioned findings and time-course of patients’ 
antibody infusion, as well as between the reversibility of symptoms and restoration of 
NMDAR levels after stopping the infusion of CSF antibodies. 
Approximately 75% of patients with anti-NMDAR encephalitis present with 
mood and psychiatric alterations ranging from manic or depressive behavior to 
psychosis, often followed by stereotyped movements, seizures, or decreased level of 
consciousness (Titulaer et al.2013;Kayser et al. 2013). Regardless of the presentation, 
most patients develop severe problems forming new memories and have amnesia of the 
disease. Close examination during the phase of recovery shows in some patients 
impairment in the visual recognition of objects or faces (e.g., physicians, nurses) 
(Frechette et al. 2011). Owing to the wide range of symptoms of the disease and lack of 
previous studies examining the distribution of brain tissue NMDAR-antibody binding 
when these antibodies are infused intraventricularly, we used standardized memory and 
behavioral tests. The most notable effects were observed in the tests of memory (novel 
object recognition) using different groups of animals in two different paradigms (open 
field and V-maze). While the first depends predominantly on normal hippocampal 
function, the second is dependent of perirhinal-hippocampal structures (Winters et al. 
2004). Compared with animals infused with control CSF, those infused with patients’ 
CSF developed progressive memory deficits, which were maximal on days 13-18 when 
the highest concentration of brain-bound NMDAR antibodies and lowest density of 
NMDAR occurred. Other paradigms affected were related to depressive-like behaviors 
(tail suspension test) and anhedonic behaviors (sucrose preference test). We did not find 
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significant abnormalities in the tests of aggression and anxiety, which are often present 
in the human disease, or in locomotor activity (an expected finding given that paralysis 
rarely occurs in patients). 
The high levels of brain-bound NMDAR antibodies between days 13-18 
suggests that after stopping the infusion of patients’ CSF on day 14, the NMDAR 
antibodies continued being distributed from mice cerebroventricular system to 
parenchyma. This distribution occurred slowly; for example, five days after starting the 
infusion of patients’ CSF the amount of NMDAR antibodies that had reached the 
hippocampus was very limited compared to that seen on days 13-18 (shown in Figure 
4B). Moreover, previous studies using cultured neurons treated with patients’ CSF 
showed that once the antibodies bound to the NMDARs, the reduction of receptors was 
microscopically visible in two hours but it took 12 hours to result in the lowest receptor 
density. Subsequently, there was a steady state of low NMDAR density for as long as 
the neurons were exposed to patients’ antibodies (Moscato et al. 2014). Together, these 
findings explain the progressive worsening of symptoms along with continued antibody 
binding and decrease of NMDAR for at least 4 days after the ventricular infusion stops 
and the subsequent recovery starts. 
Although the hippocampus was the region with the highest concentration of 
brain-bound NMDAR antibodies, these antibodies were also extracted from cerebral 
cortex or cerebellum though at much lower levels. The higher concentration of 
antibodies and predominant decrease of NMDAR in the hippocampus are consistent 
with the predominant binding of human antibodies to this brain region when sections of 
rodent brain are directly incubated with patients’ antibodies (Dalmau et al., 2007; 
Moscato et al. 2014). Additionally, because of the close spatial relationship to the 
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ventricles, the intraventricular infusion of human CSF antibodies might have 
contributed to the preferential binding to the hippocampus.  
The correlation between the concentration of brain-bound antibodies and 
selective reduction of NMDAR cluster density and protein concentration was similar to 
that reported using in vitro studies with cultured rat hippocampal neurons (Hughes et 
al., 2012; Moscato et al. 2014). Moreover, autopsies of patients with anti-NMDAR 
encephalitis showed that the hippocampal regions with highest concentration of brain-
bound antibodies were also the areas with lower expression of NMDAR (Dalmau et al., 
2007). In the current model, patients’ antibodies did not alter AMPAR cluster density or 
protein concentration; these findings are in line with those reported with cultured 
neurons where the clusters of AMPAR and AMPAR-mediated currents were not 
directly affected (Hughes et al., 2010). These experiments, however, did not explore 
whether paradigms, that normally induce long-term potentiation, and therefore increase 
the number of synaptic AMPAR, were altered by patients’ antibodies. Mikasova and 
colleagues showed that neurons exposed to patients’ NMDAR antibodies failed to show 
an increase in cell surface AMPAR after induction of chemical long-term potentiation 
(Mikasova et al., 2012). Another study examining the acute metabolic effects of 
patients’ antibodies after injection into rat brain showed impairment of NMDA and 
AMPA-mediated synaptic function (Manto et al. 2010). In the present model, we did 
not perform electrophysiological studies on acute slices of brain (a goal of future 
studies); however, there is reported evidence that patients’ NMDAR antibodies suppress 
induction of long-term potentiation when directly applied to mouse hippocampal slices 
(Zhang et al. 2012). Work with cultured neurons indicates that the decrease of synaptic 
NMDAR currents is likely a result of the antibody-mediated low receptor levels, as no 
direct antibody blockade was detected (Moscato et al. 2014). 
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Our study has limitations related to the type of disease and symptoms to model. 
For example, different from other models of antibody-mediated CNS disorders where 
the antibodies result in characteristic symptoms (e.g., amphiphysin antibodies and 
visible muscle spasms) (Sommer et al. 2005) or focal deficits with visible tissue 
changes (e.g., aquaporin4 antibodies and neuromyelitis optica) (Hinson et al. 
2012;Bradl and Lassmann 2014), anti-NMDAR encephalitis results in a broader 
spectrum of symptoms where memory and behavioral deficits occur early, and the 
structural alterations are not visible unless the NMDAR clusters or protein 
concentration are measured. It is not surprising that in the current model the full 
spectrum of symptoms, such as seizures, dyskinesias or coma, did not occur. Studies 
with NMDAR antagonists have shown that the progression of symptoms (from 
behavioral and memory deficits to unresponsiveness with catatonic features and coma) 
correlated with the intensity of the decrease of receptor function (Javitt and Zukin 
1991). Therefore, it is likely that prolonged infusion or higher concentration of patients’ 
antibodies would cause additional symptoms. This is supported by the current model, in 
which the time course of symptom development, brain-bound antibody concentration, 
and decrease of synaptic NMDAR correlated well with each other.  Future experiments 
using prolonged infusion or higher concentration of patients’ antibodies may also result 
in symptoms beyond hippocampal-parahippocampal regions. Compared with the 
hippocampus, other brain regions normally have lower density of NMDAR, and 
appeared to be less accessible to the ventricularly infused antibodies. Direct injection of 
antibodies into those brain regions can be considered, but we previously tried bilateral 
hippocampal infusion using the same osmotic pump approach, resulting in more limited 
antibody diffusion and no symptoms (A Jain et al, data not published). Moreover, the 
phenotype of the current model is likely influenced by the strain of mice. In this study 
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we used C57BL6/J mice because we were interested in the effects on memory and 
behavior, but this strain is one of the most resistant to develop seizures (Ferraro et al. 
2002). 
The antibody-induced depletion of synaptic NMDAR along with the similarities 
between the human disease and the phenotypes induced by NMDAR antagonists 
(phencyclidine, ketamine or MK801) have suggested points of convergence with one of 
the most influential theories of schizophrenia, the NMDA-hypofunction model (Olney 
and Farber 1995; Kehrer et al. 2008). The presence of positive (hallucinations, 
delusions, hyperactivity) and negative (decreased motivation, flat affect, deficit of 
memory and learning) symptoms is however not identical among the drug-induced 
phenotypes and also varies among animal species (Javitt and Zukin 1991). It has been 
suggested that NMDAR-bearing parvalbumin positive GABAergic interneurons are 
disproportionally more sensitive to NMDAR antagonists than other neurons (Li et al. 
2002). Interestingly, a genetic model of partial ablation of the GluN1 subunit of 
NMDAR in corticolimbic GABAergic interneurons resulted in symptoms partially 
resembling our GluN1 immunological model of receptor depletion, including memory 
deficits and anhedonic behaviors (Belforte et al, 2010) Differences related to the 
underlying mechanisms (pharmacologic blockade, genetic or immunologic NMDAR 
depletion) and regions where the NMDAR function is depleted (general, mesolimbic, or 
hippocampal-parahippocampal) likely influence the clinical phenotypes.  
Overall, the current findings provide robust evidence that antibodies from 
patients with anti-NMDAR encephalitis alter memory and behavior through reduction 
of cell-surface and synaptic NMDAR, and therefore support the use of treatments 
directed at decreasing the levels of antibodies or antibody-producing cells. This 
approach can now be adapted to 1) model other aspects of the disease by changing the 
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duration and dosing of antibody infusion, or strain of mice, 2) investigate other 
disorders of memory and behavior that occur in association with antibodies against 
other cell surface or synaptic proteins, such as AMPAR or GABA(B)R (Lai et al. 2009; 
Lancaster et al. 2010), and 3) determine whether compounds such as Ephrin-B2 ligand 
that has been shown to prevent the destabilizing NMDAR crosslinking effects of 
patients’ antibodies improve or alter the course of the disease (Mikasova et al., 2012).  
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Legends to Figures 
Figure 1: Experimental design and placement of ventricular catheters 
(A) Representative coronal mouse brain section with catheter placement. Scale bar=2 
mm.  
(B, C) Coronal and sagittal mouse brain sections demonstrating cerebroventricular 
diffusion of methylene blue after ventricular infusion. Scale bars=2 mm.  
(D) Schedule of cognitive testing and animal sacrifice. At day 0, catheters and osmotic 
pumps were placed and bilateral ventricular infusion of patients’ or control CSF started. 
Infusion lasted for 14 days. Memory (novel object recognition [NOR]), anhedonia 
(sucrose preference test [ANH]), depressive-like behavior (tail suspension test [TST] 
and forced swimming test [FST]), anxiety (black and white test [BW] and elevated plus 
maze test [EPM]), aggressiveness (resident intruder test [RI]) and locomotor activity 
(LOC) were assessed blinded to treatment at the indicated days. The NOR was assessed 
in open field and V-maze paradigms in two different cohorts of mice. Animals were 
habituated for 1 to 4 days before surgery (baseline) to NOR, ANH, and LOC. Red 
arrowheads indicate the days of sacrifice for studies of effects of antibodies in brain.  
 
Figure 2: Infusion of CSF from patients with NMDAR antibodies causes deficits in 
memory, anhedonia, and depressive-like behavior  
(A,B) Novel object recognition (NOR) index in open field (A) or V-maze paradigms. 
(B) in animals treated with patients’ CSF (grey circles) or control CSF (white circles) A 
high index indicates better object recognition memory.  
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(C) Preference for sucrose-containing water in animals infused with patients CSF (grey) 
or control CSF (white). Lower percentages indicate anhedonia.  
(D,E) Total time of immobility in tail-suspension test during the infusion period (D, day 
12) and in forced swimming test after the infusion period (E, day 20). Data are 
presented as mean ± s.e.m (median ± IQR in D).  
Number of animals: Patients’ CSF n=18 (open field NOR n=8), control CSF n=20 (open 
field NOR n=10). Significance of treatment effect was assessed by two-way ANOVA 
(A-C) with an α-error of 0.05 and post-hoc testing with Sidak-Holm adjustment 
(asterisks), unpaired t-test (E) or Mann-Whitney U test (D). * P<0.05, *** P<0.001. See 
Supplemental Table 1 for detailed statistics.  
 
Figure 3: Infusion of CSF from patients with NMDAR antibodies does not alter the 
tests of anxiety, aggression, and locomotor activity 
(A, B) Number of entries into bright/open compartments during a five minute period in 
a standard black & white (A, day 6) or elevated plus maze test (B, day 14) in animals 
treated with patients’ CSF (grey circles) or control CSF (white circles).  
(C) Number of aggressive events over a four-minute period in a resident intruder 
paradigm in both treatment groups.  
(D) Horizontal (solid lines) and vertical (dashed lines) movement count over a ten 
minute period in both treatment groups.  
Data are presented as mean ± s.e.m. Number of animals: Patients’ CSF n=18, control 
CSF n=20. Statistical assessment as indicated in Figure 2, and Supplemental Table 1. 
 
Figure 4: Animals infused with patient’s CSF have a progressive increase of 
human IgG bound to hippocampus  
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(A, B) Immunostaining of human IgG in sagittal brain sections (A) and hippocampus 
(B) of representative animals infused with patients’ CSF (left panels) and control CSF 
(right panels), sacrificed at the indicated experimental days. In animals infused with 
patients’ CSF there is a gradual increase of IgG immunostaining until day 18, followed 
by decrease of immunostaining. Scale bar in A=2 mm; scale bar in B=200 µm.  
(C) Quantification of intensity of human IgG immunolabeling in hippocampus of mice 
infused with patients’ CSF (grey columns) and control CSF (white columns) sacrificed 
at the indicated time points.  
(D-H) Confocal microscopy analysis of IgG bound to the hippocampus on day 18. (D) 
Sagittal section of the hippocampus with areas examined at higher magnification in E 
(arrow in CA1), F (arrow heads in CA3) and G (asterisks in dentage gyrus [DG]). Note 
the fine punctate IgG immunolabeling surrounding neuronal bodies in mice infused with 
patients CSF; this immunolabeling is similar to that reported in brain sections directly 
incubated with patients’ antibodies, as in (Dalmau et al. 2008). Scale bar in D=200 µm; 
scale bars in E-G=10 µm.  
(H) Quantification of the intensity of human IgG immunofluorescence in the indicated 
areas in animals infused with patients’ CSF (grey columns) or control CSF (white 
columns).  
For all quantifications, mean intensity of IgG immunostaining in the group with the 
highest value (animals treated with patients’ CSF and sacrificed at day 18) was defined 
as 100%. All data are presented as mean ± s.e.m.  For each time point 5 animals infused 
with patients’ CSF and 5 with control CSF were examined. Significance of treatment 
effect was assessed by two-way ANOVA with an α-error of 0.05 (*) and post-hoc 
testing with Sidak-Holm adjustment ($). ***, $$$ P<0.001; $, P<0.05. See 
Supplemental Table 2 for detailed statistics. 
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Figure 5: The human IgG extracted from brain of mice infused with patients’ CSF 
is specific for NMDARs 
(A,B) HEK293 cells expressing the GluN1 subunit of the NMDAR immunolabeled with 
acid-extracted IgG fractions (top row in A) or pre-extraction fractions (top row in B) 
from hippocampus of mice infused with patients’ CSF and sacrificed on the indicated 
days. The maximal reactivity with GluN1-expressing cells was noted in acid-extracted 
IgG fractions from days 13 and 18 (A); none of the pre-extraction fractions showed 
GluN1 reactivity (B) indicating that the reactivity of acid-extracted fractions 
corresponds to IgG antibodies that were bound to brain NMDAR receptors. The second 
row in A and B shows the reactivity with a monoclonal GluN1 antibody, and the third 
row the co-localization of immunolabeling. Scale bars=10µm.  
(C) Quantification of NMDAR antibody titer in IgG-extracted fractions from 
hippocampus of animals treated with patients’ CSF (n= 5 mice per each time point, 
except 4 mice for day 5). Solid line = median. Significance was tested by Kruskal-
Wallis with an α-error of 0.05 (asterisks) and post-hoc testing with Dunn’s test ($). 
**,$$ P<0.01, ***,$$$ P<0.001. See Supplemental Table 2 for detailed statistics.  
(D, E) HEK293 cells expressing the GluN1 subunit of the NMDAR immunolabeled 
with acid-extracted IgG fractions (D) and pre-extraction fractions (E) from 
hippocampus, cerebral cortex (Ctx) and cerebellum (Cb) of mice infused with patients’ 
CSF (day 18). The acid-extracted IgG fraction from hippocampus showed higher level 
of NMDAR antibodies than those extracted from cerebral cortex (ctx) and cerebellum 
(Cb). Scale bars=10µm.              
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Figure 6: Patients’ NMDAR antibodies selectively reduce the density of total and 
synaptic NMDAR clusters in hippocampus of mice 
(A) Hippocampus of mice infused for 14 days (day 18) with patients’ CSF (upper row) 
or control CSF (lower row) immunolabeled for PSD95 and NMDAR. Images were 
merged (merge) and post-processed to demonstrate co-localizing clusters 
(colocalization). Squares in “colocalization” indicate the analyzed areas in CA1, CA3 
and DG. Scale bar=200 µm.  
(B) 3D projection and analysis of the density of total clusters of PSD95 and NMDAR, 
and synaptic clusters of NMDAR (defined as NMDAR clusters colocalizing with 
PSD95) in a representative CA3 region (square in A “colocalization”). Merged images 
(merge, PSD95 green, NMDAR red) were post-processed and used to calculate the 
density of clusters (density=spots/µm3). Scale bar=2 µm.  
(C-F) Quantification of the density of total (C) and synaptic (D) NMDAR clusters, 
PSD95 clusters (E), and total/synaptic AMPAR clusters (day 18 only, F) in a pooled 
analysis of hippocampal subregions (CA1, CA3, DG) in animals treated with patients’ 
CSF (grey) or control CSF (white) on the indicated days. Mean density of clusters in 
control CSF treated animals was defined as 100%. Data are presented as mean ± s.e.m. 
For each time point 5 animals infused with patients’ CSF and 5 with control CSF were 
examined. Significance of treatment effect was assessed by two-way ANOVA with an 
α-error of 0.05 (asterisks) and post-hoc testing with Sidak-Holm adjustment ($) (C,D,E) 
or unpaired t-test (F). *,$ P< 0.05; **,$$ P< 0.01; ***,$$$ P<0.001.  See Supplemental 
Table 2 for detailed statistics.  
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Figure 7: Patients’ NMDAR antibodies selectively reduce the protein 
concentration of NMDAR in hippocampus of mice  
A) Representative immunoblots of proteins extracted from hippocampus of animals 
infused with patients’ CSF (P) or control CSF (C) sacrificed at the indicated time points 
and probed for expression of GluN1 (NMDAR), PSD95 and β-Actin (loading control).  
Note that there is less visible GluN1 expression on days 13 and 18.  
(B, D, E) Quantification of total NMDAR (B), PSD95 (D) or AMPAR (E) protein in 
animals treated with patients’ CSF (grey columns) or control CSF (white columns) 
sacrificed at the indicated time points (AMPAR day 18 only, E). Results were 
normalized to β-Actin (loading control). Mean band density of animals treated with 
control CSF was defined as 100%. Data are presented as mean ± s.e.m. For each time 
point 6 animals infused with patients’ CSF and 6 with control CSF were examined (for 
days 26 and 46, only 5 animals treated with patient’s CSF were available). Significance 
of treatment effect was assessed by two-way ANOVA with an α-error of 0.05 (asterisks) 
and post-hoc testing with Sidak-Holm adjustment ($). $$ P< 0.01; *** P< 0.001. See 
Supplemental Table 2 for detailed statistics 
(C) Correlation between concentration of human IgG bound to hippocampus (x-axis, 
highest hippocampal IgG intensity was defined as 100%) and hippocampal NMDAR 
protein concentration in mice sacrificed on day 18 (R2=0.69, p=0.003). Grey circles: 
mice infused with patients’ CSF (n=5), white circles: mice infused with control CSF 
(n=5). 
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Figure 8: Absence of neuronal apoptosis, deposits of complement, and lymphocytic 
infiltrates in the hippocampus of mice infused with patients’ CSF  
(A,B) TUNEL and cleaved caspase 3 immunolabeling of a representative area of CA3 
(area with maximal IgG binding and lower NMDAR concentration) of an animal 
infused with patients CSF, showing lack of apoptotic cells. A section of the same region 
in an animal with transient middle cerebral artery occlusion (stroke model) shows 
apoptotic cells in the penumbra (panel on the left). 
(C) Same CA3 region as in (A) immunostained for C5b-9 showing lack of deposit of 
complement. A section of the same region in the indicated stroke model shows presence 
of complement in the penumbra (panel on the left). 
(D,E) Same CA3 region as in (A) immunostained for T (CD3) and B (CD45R) 
lymphocytes showing absence of inflammatory infiltrates. A section of spleen was used 
as control tissue showing the presence of CD3 (green) and CD45R (red) cells. Scale 
bar=10 µm. Total number of animals examined: patients’ CSF n=5; control CSF n=5. 
Scale bars=20µm.  
Page 32 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
32 
 
 
References 
Aso E, Ozaita A, Valdizan EM et al. BDNF impairment in the hippocampus is related to 
enhanced despair behavior in CB1 knockout mice. J Neurochem 2008; 105: 565-572. 
Banovic D, Khorramshahi O, Owald D et al. Drosophila neuroligin 1 promotes growth 
and postsynaptic differentiation at glutamatergic neuromuscular junctions. Neuron 
2010; 66: 724-738. 
Belforte JE, Zsiros V, Sklar ER et al. Postnatal NMDA receptor ablation in 
corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010; 
13: 76-83. 
Berrendero F, Mendizabal V, Robledo P et al. Nicotine-induced antinociception, 
rewarding effects, and physical dependence are decreased in mice lacking the 
preproenkephalin gene. J Neurosci 2005; 25: 1103-1112. 
Bradl M, Lassmann H. Experimental models of neuromyelitis optica. Brain Pathol 
2014; 24: 74-82. 
Bura AS, Guegan T, Zamanillo D, Vela JM, Maldonado R. Operant self-administration 
of a sigma ligand improves nocic ptive and emotional manifestations of neuropathic 
pain. Eur J Pain 2013; 17: 832-843. 
Bura SA, Burokas A, Martin-Garcia E, Maldonado R. Effects of chronic nicotine on 
food intake and anxiety-like behaviour in CB(1) knockout mice. Eur 
Neuropsychopharmacol 2010; 20: 369-378. 
Bura SA, Castane A, Ledent C, Valverde O, Maldonado R. Genetic and 
pharmacological approaches to evaluate the interaction between the cannabinoid and 
cholinergic systems in cognitive processes. Br J Pharmacol 2007; 150: 758-765. 
Burokas A, Gutierrez-Cuesta J, Martin-Garcia E, Maldonado R. Operant model of 
frustrated expected reward in mice. Addict Biol 2012; 17: 770-782. 
Caille S, Espejo EF, Reneric JP, Cador M, Koob GF, Stinus L. Total neurochemical 
lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-
precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine 
to reverse opiate withdrawal. J Pharmacol Exp Ther 1999; 290: 881-892. 
Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the 
anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980; 13: 167-170. 
Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA-receptor encephalitis: case 
series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098. 
Dalmau J, Tuzun E, Wu HY et al. Paraneoplastic anti-N-methyl-D-aspartate receptor 
encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36. 
Page 33 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
33 
 
Ennaceur A. One-trial object recognition in rats and mice: methodological and 
theoretical issues. Behav Brain Res 2010; 215: 244-254. 
Ferraro TN, Golden GT, Smith GG, DeMuth D, Buono RJ, Berrettini WH. Mouse strain 
variation in maximal electroshock seizure threshold. Brain Res 2002; 936: 82-86. 
Filliol D, Ghozland S, Chluba J et al. Mice deficient for delta- and mu-opioid receptors 
exhibit opposing alterations of emotional responses. Nat Genet 2000; 25: 195-200. 
Frechette ES, Zhou L, Galetta SL, Chen L, Dalmau J. Prolonged follow-up and CSF 
antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology 2011; 76: 
S64-S66. 
Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR. Anti-NMDA Receptor 
Encephalitis Antibody Binding Is Dependent on Amino Acid Identity of a Small Region 
within the GluN1 Amino Terminal Domain. J Neurosci 2012; 32: 11082-11094. 
Gresa-Arribas N, Titulaer MJ, Torrents A et al. Antibody titres at diagnosis and during 
follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 
2014; 13: 167-177. 
Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the 
human brain. Brain Res Rev 2009; 60: 279-286. 
Hahn CG, Wang HY, Cho DS et al. Altered neuregulin 1-erbB4 signaling contributes to 
NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12: 824-828. 
Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a 
maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch 
Pharmacol 1984; 327: 1-5. 
Hinson SR, Romero MF, Popescu BF et al. Molecular outcomes of neuromyelitis optica 
(NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109: 
1245-1250. 
Hughes EG, Peng X, Gleichman AJ et al. Cellular and synaptic mechanisms of anti-
NMDA receptor encephalitis. J Neurosci 2010; 30: 5866-5875. 
Iizuka T, Sakai F, Ide T et al. Anti-NMDA receptor encephalitis in Japan: long-term 
outcome without tumor removal. Neurology 2008; 70: 504-511. 
Irani SR, Bera K, Waters P et al. N-methyl-D-aspartate antibody encephalitis: temporal 
progression of clinical and paraclinical observations in a predominantly non-
paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667. 
Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am 
J Psychiatry 1991; 148: 1301-1308. 
Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA 
receptor hypofunction to the dopamine hypothesis of schizophrenia. 
Neuropsychopharmacology 1999; 20: 201-225. 
Page 34 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
34 
 
Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of 
isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA 
Neurol 2013; 70: 1133-1139. 
Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered Excitatory-Inhibitory Balance 
in the NMDA-Hypofunction Model of Schizophrenia. Front Mol Neurosci 2008; 1: 6. 
Konig M, Zimmer AM, Steiner H et al. Pain responses, anxiety and aggression in mice 
deficient in pre-proenkephalin. Nature 1996; 383: 535-538. 
Lai M, Hughes EG, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter 
synaptic receptor location. Ann Neurol 2009; 65: 424-434. 
Lancaster E, Lai M, Peng X et al. Antibodies to the GABA(B) receptor in limbic 
encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 
2010; 9: 67-76. 
Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and 
neuropsychiatric disorders. Nat Rev Neurosci 2007; 8: 413-426. 
Li Q, Clark S, Lewis DV, Wilson WA. NMDA receptor antagonists disinhibit rat 
posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J 
Neurosci 2002; 22: 3070-3080. 
Llorente-Berzal A, Puighermanal E, Burokas A et al. Sex-dependent 
psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent 
drug consumption. PLoS ONE 2013; 8: e78386. 
Maldonado JE, Kyle RA, Ludwig J, et al. Meningeal myeloma. Arch Intern Med 1970; 
126: 660-663. 
Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies 
from patients with anti-NMDA receptor encephalitis: further evidence of synaptic 
glutamatergic dysfunction. Orphanet J Rare Dis 2010; 5: 31. 
Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, 
Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-
NMDAR encephalitis. Neurology 2011; 77: 589-593. 
Mikasova L, De RP, Bouchet D et al. Disrupted surface cross-talk between NMDA and 
Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012; 135: 1606-1621. 
Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor 
expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436. 
Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute 
mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor 
encephalitis. Ann Neurol 2014; 76: 108-190.  
Mouri A, Noda Y, Noda A et al. Involvement of a dysfunctional dopamine-D1/N-
methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in 
Page 35 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
35 
 
the impairment of latent learning in a model of schizophrenia induced by phencyclidine. 
Mol Pharmacol 2007; 71: 1598-1609. 
Olney JW and Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen 
Psychiatry 1995; 52: 998-1007. 
Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for 
antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336. 
Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. 
Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR 
signaling. Nat Neurosci 2009; 12: 1152-1158. 
Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates 
revisited). Immunol Today 1993; 14: 426-430. 
Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor 
trafficking. Annu Rev Cell Dev Biol 2007; 23: 613-643. 
Snyder EM, Nong Y, Almeida CG et al. Regulation of NMDA receptor trafficking by 
amyloid-beta. Nat Neurosci 2005; 8: 1051-1058. 
Sommer C, Weishaupt A, Brinkhoff J et al. Paraneoplastic stiff-person syndrome: 
passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365: 
1406-1411. 
Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for 
screening antidepressants in mice. Psychopharmacology (Berl) 1985; 85: 367-370. 
Strekalova T, Gorenkova N, Schunk E, Dolgov O, Bartsch D. Selective effects of 
citalopram in a mouse model of stress-induced anhedonia with a control for chronic 
stress. Behav Pharmacol 2006; 17: 271-287. 
Taglialatela G, Hogan D, Zhang WR, Dineley KT. Intermediate- and long-term 
recognition memory deficits in Tg2576 mice are reversed with acute calcineurin 
inhibition. Behav Brain Res 2009; 200: 95-99. 
Titulaer MJ, McCracken L, Gabilondo I et al. Treatment and prognostic factors for 
long-term outcome in patients with anti-NMDA receptor encephalitis: an observational 
cohort study. Lancet Neurol 2013; 12: 157-165. 
Viaccoz A, Desestret V, Ducray F et al. Clinical specificities of adult male patients with 
NMDA receptor antibodies encephalitis. Neurology 2014; 82: 556-563. 
Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the 
emergency department: a case series. J Emerg Med 2000; 18: 447-451. 
Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ. Double dissociation 
between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object 
recognition and spatial memory: heterogeneity of function within the temporal lobe. J 
Neurosci 2004; 24: 5901-5908. 
Page 36 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
36 
 
 
Zhang Q, Tanaka K, Sun P et al. Suppression of synaptic plasticity by cerebrospinal 
fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 2012; 45: 610-615. 
 
Page 37 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
  
 
 
Figure 1: Experimental design and placement of ventricular catheters  
(A) Representative coronal mouse brain section with catheter placement. Scale bar=2 mm.  
(B, C) Coronal and sagittal mouse brain sections demonstrating cerebroventricular diffusion of methylene 
blue after ventricular infusion. Scale bars=2 mm.  
(D) Schedule of cognitive testing and animal sacrifice. At day 0, catheters and osmotic pumps were placed 
and bilateral ventricular infusion of patients’ or control CSF started. Infusion lasted for 14 days. Memory 
(novel object recognition [NOR]), anhedonia (sucrose preference test [ANH]), depressive-like behavior (tail 
suspension test [TST] and forced swimming test [FST]), anxiety (black and white test [BW] and elevated 
plus maze test [EPM]), aggressiveness (resident intruder test [RI]) and locomotor activity (LOC) were 
assessed blinded to treatment at the indicated days. The NOR was assessed in open field and V-maze 
paradigms in two different cohorts of mice. Animals were habituated for 1 to 4 days before surgery 
(baseline) to NOR, ANH, and LOC. Red arrowheads indicate the days of sacrifice for studies of effects of 
antibodies in brain.  
155x93mm (300 x 300 DPI)  
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Figure 2: Infusion of CSF from patients with NMDAR antibodies causes deficits in memory, anhedonia, and 
depressive-like behavior  
(A,B) Novel object recognition (NOR) index in open field (A) or V-maze paradigms.  
(B) in animals treated with patients’ CSF (grey circles) or control CSF (white circles) A high index indicates 
better object recognition memory.  
(C) Preference for sucrose-containing water in animals infused with patients CSF (grey) or control CSF 
(white). Lower percentages indicate anhedonia.  
(D,E) Total time of immobility in tail-suspension test during the infusion period (D, day 12) and in forced 
swimming test after the infusion period (E, day 20). Data are presented as mean ± s.e.m (median ± IQR in 
D).  
Number of animals: Patients’ CSF n=18 (open field NOR n=8), control CSF n=20 (open field NOR n=10). 
Significance of treatment effect was assessed by two-way ANOVA (A-C) with an α-error of 0.05 and post-hoc 
testing with Sidak-Holm adjustment (asterisks), unpaired t-test (E) or Mann-Whitney U test (D). * P<0.05, 
*** P<0.001. See Supplemental Table 1 for detailed statistics.  
125x80mm (300 x 300 DPI)  
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Figure 3: Infusion of CSF from patients with NMDAR antibodies does not alter the tests of anxiety, 
aggression, and locomotor activity  
(A, B) Number of entries into bright/open compartments during a five minute period in a standard black & 
white (A, day 6) or elevated plus maze test (B, day 14) in animals treated with patients’ CSF (grey circles) 
or control CSF (white circles).  
(C) Number of aggressive events over a four-minute period in a resident intruder paradigm in both 
treatment groups.  
(D) Horizontal (solid lines) and vertical (dashed lines) movement count over a ten minute period in both 
treatment groups.  
Data are presented as mean ± s.e.m. Number of animals: Patients’ CSF n=18, control CSF n=20. Statistical 
assessment as indicated in Figure 2, and Supplemental Table 1.  
122x119mm (300 x 300 DPI)  
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Figure 4: Animals infused with patient’s CSF have a progressive increase of human IgG bound to 
hippocampus  
(A, B) Immunostaining of human IgG in sagittal brain sections (A) and hippocampus (B) of representative 
animals infused with patients’ CSF (left panels) and control CSF (right panels), sacrificed at the indicated 
experimental days. In animals infused with patients’ CSF there is a gradual increase of IgG immunostaining 
until day 18, followed by decrease of immunostaining. Scale bar in A=2 mm; scale bar in B=200 µm.  
(C) Quantification of intensity of human IgG immunolabeling in hippocampus of mice infused with patients’ 
CSF (grey columns) and control CSF (white columns) sacrificed at the indicated time points.  
(D-H) Confocal microscopy analysis of IgG bound to the hippocampus on day 18. (D) Sagittal section of the 
hippocampus with areas examined at higher magnification in E (arrow in CA1), F (arrow heads in CA3) and 
G (asterisks in dentage gyrus [DG]). Note the fine punctate IgG immunolabeling surrounding neuronal 
bodies in mice infused with patients CSF; this immunolabeling is similar to that reported in brain sections 
directly incubated with patients’ antibodies, as in (Dalmau et al. 2008). Scale bar in D=200 µm; scale bars 
in E-G=10 µm.  
(H) Quantification of the intensity of human IgG immunofluorescence in the indicated areas in animals 
infused with patients’ CSF (grey columns) or control CSF (white columns).  
For all quantifications, mean intensity of IgG immunostaining in the group with the highest value (animals 
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treated with patients’ CSF and sacrificed at day 18) was defined as 100%. All data are presented as mean ± 
s.e.m.  For each time point 5 animals infused with patients’ CSF and 5 with control CSF were examined. 
Significance of treatment effect was assessed by two-way ANOVA with an α-error of 0.05 (*) and post-hoc 
testing with Sidak-Holm adjustment ($). ***, $$$ P<0.001; $, P<0.05. See Supplemental Table 2 for 
detailed statistics.  
186x204mm (300 x 300 DPI)  
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Figure 5: The human IgG extracted from brain of mice infused with patients’ CSF is specific for NMDARs  
(A,B) HEK293 cells expressing the GluN1 subunit of the NMDAR immunolabeled with acid-extracted IgG 
fractions (top row in A) or pre-extraction fractions (top row in B) from hippocampus of mice infused with 
patients’ CSF and sacrificed on the indicated days. The maximal reactivity with GluN1-expressing cells was 
noted in acid-extracted IgG fractions from days 13 and 18 (A); none of the pre-extraction fractions showed 
GluN1 reactivity (B) indicating that the reactivity of acid-extracted fractions corresponds to IgG antibodies 
that were bound to brain NMDAR receptors. The second row in A and B shows the reactivity with a 
monoclonal GluN1 antibody, and the third row the co-localization of immunolabeling. Scale bars=10µm.  
(C) Quantification of NMDAR antibody titer in IgG-extracted fractions from hippocampus of animals treated 
with patients’ CSF (n= 5 mice per each time point, except 4 mice for day 5). Solid line = median. 
Significance was tested by Kruskal-Wallis with an α-error of 0.05 (asterisks) and post-hoc testing with 
Dunn’s test ($). **,$$ P<0.01, ***,$$$ P<0.001. See Supplemental Table 2 for detailed statistics.  
(D, E) HEK293 cells expressing the GluN1 subunit of the NMDAR immunolabeled with acid-extracted IgG 
fractions (D) and pre-extraction fractions (E) from hippocampus, cerebral cortex (Ctx) and cerebellum (Cb) 
of mice infused with patients’ CSF (day 18). The acid-extracted IgG fraction from hippocampus showed 
higher level of NMDAR antibodies than those extracted from cerebral cortex (ctx) and cerebellum (Cb). Scale 
bars=10µm.  
164x103mm (300 x 300 DPI)  
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Figure 6: Patients’ NMDAR antibodies selectively reduce the density of total and synaptic NMDAR clusters in 
hippocampus of mice  
(A) Hippocampus of mice infused for 14 days (day 18) with patients’ CSF (upper row) or control CSF (lower 
row) immunolabeled for PSD95 and NMDAR. Images were merged (merge) and post-processed to 
demonstrate co-localizing clusters (colocalization). Squares in “colocalization” indicate the analyzed areas in 
CA1, CA3 and DG. Scale bar=200 µm.  
(B) 3D projection and analysis of the density of total clusters of PSD95 and NMDAR, and synaptic clusters of 
NMDAR (defined as NMDAR clusters colocalizing with PSD95) in a representative CA3 region (square in A 
“colocalization”). Merged images (merge, PSD95 green, NMDAR red) were post-processed and used to 
calculate the density of clusters (density=spots/µm3). Scale bar=2 µm.  
(C-F) Quantification of the density of total (C) and synaptic (D) NMDAR clusters, PSD95 clusters (E), and 
total/synaptic AMPAR clusters (day 18 only, F) in a pooled analysis of hippocampal subregions (CA1, CA3, 
DG) in animals treated with patients’ CSF (grey) or control CSF (white) on the indicated days. Mean density 
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of clusters in control CSF treated animals was defined as 100%. Data are presented as mean ± s.e.m. For 
each time point 5 animals infused with patients’ CSF and 5 with control CSF were examined. Significance of 
treatment effect was assessed by two-way ANOVA with an α-error of 0.05 (asterisks) and post-hoc testing 
with Sidak-Holm adjustment ($) (C,D,E) or unpaired t-test (F). *,$ P< 0.05; **,$$ P< 0.01; ***,$$$ 
P<0.001.  See Supplemental Table 2 for detailed statistics.  
161x231mm (300 x 300 DPI)  
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Figure 7: Patients’ NMDAR antibodies selectively reduce the protein concentration of NMDAR in hippocampus 
of mice  
A) Representative immunoblots of proteins extracted from hippocampus of animals infused with patients’ 
CSF (P) or control CSF (C) sacrificed at the indicated time points and probed for expression of GluN1 
(NMDAR), PSD95 and β-Actin (loading control).  Note that there is less visible GluN1 expression on days 13 
and 18.  
(B, D, E) Quantification of total NMDAR (B), PSD95 (D) or AMPAR (E) protein in animals treated with 
patients’ CSF (grey columns) or control CSF (white columns) sacrificed at the indicated time points (AMPAR 
day 18 only, E). Results were normalized to β-Actin (loading control). Mean band density of animals treated 
with control CSF was defined as 100%. Data are presented as mean ± s.e.m. For each time point 6 animals 
infused with patients’ CSF and 6 with control CSF were examined (for days 26 and 46, only 5 animals 
treated with patient’s CSF were available). Significance of treatment effect was assessed by two-way ANOVA 
with an α-error of 0.05 (asterisks) and post-hoc testing with Sidak-Holm adjustment ($). $$ P< 0.01; *** 
P< 0.001. See Supplemental Table 2 for detailed statistics  
(C) Correlation between concentration of human IgG bound to hippocampus (x-axis, highest hippocampal 
IgG intensity was defined as 100%) and hippocampal NMDAR protein concentration in mice sacrificed on day 
18 (R2=0.69, p=0.003). Grey circles: mice infused with patients’ CSF (n=5), white circles: mice infused 
with control CSF (n=5).  
105x65mm (300 x 300 DPI)  
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Figure 8: Absence of neuronal apoptosis, deposits of complement, and lymphocytic infiltrates in the 
hippocampus of mice infused with patients’ CSF  
(A,B) TUNEL and cleaved caspase 3 immunolabeling of a representative area of CA3 (area with maximal IgG 
binding and lower NMDAR concentration) of an animal infused with patients CSF, showing lack of apoptotic 
cells. A section of the same region in an animal with transient middle cerebral artery occlusion (stroke 
model) shows apoptotic cells in the penumbra (panel on the left).  
(C) Same CA3 region as in (A) immunostained for C5b-9 showing lack of deposit of complement. A section 
of the same region in the indicated stroke model shows presence of complement in the penumbra (panel on 
the left).  
(D,E) Same CA3 region as in (A) immunostained for T (CD3) and B (CD45R) lymphocytes showing absence 
of inflammatory infiltrates. A section of spleen was used as control tissue showing the presence of CD3 
(green) and CD45R (red) cells. Scale bar=10 µm. Total number of animals examined: patients’ CSF n=5; 
control CSF n=5. Scale bars=20µm.  
180x168mm (300 x 300 DPI)  
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Behavioral animal tests and references 
Supplemental Tables 1 and 2 
Supplemental Figures 1 and 2 
 
Behavioral animal tests 
Novel object recognition (NOR) test: This test was performed in two paradigms, open field 
(45x45x40 cm, Panlab, Spain) and in V-maze (40 cm per side, Panlab, Spain) using two different 
groups of animals, as reported by us and others [Bura et al. 2007;Taglialatela et al. 
2009;Puighermanal et al. 2009]. On day 1 (same day of osmotic pump implantation, before 
surgery) mice were habituated for 30 minutes in the open field arena, or 9 minutes in the V-
maze. On days 3, 10, 18 and 25, mice were put back into the open field arena or into the V-maze 
for 9 minutes; two identical objects were presented, and the time the mice spent exploring each 
object was recorded. After a retention phase of 3 hours, the mice were placed for another 9 
minutes into the open field arena or into the V-maze; in each paradigm one of the familiar 
objects was replaced with a novel object and the total time spent exploring each object (novel 
and familiar) was registered. During the test phase of the open field paradigm, the objects were 
positioned in the opposite corners of those used in the training phase and the novel object was 
presented in 50% of trials on the right and in 50% of trials on the left side. Object exploration 
was defined as the orientation of the nose to the object at a distance of less than 2 cm. A 
discrimination index was calculated as the difference of the time spent exploring the novel and 
the time spent exploring the familiar object divided by the total time exploring both objects. A 
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higher discrimination index is considered to reflect greater memory retention for the familiar 
object [Puighermanal, Marsicano, Busquets-Garcia, Lutz, Maldonado, and Ozaita2009;Ennaceur 
2010]. 
 
Sucrose preference test: This test was performed on days 10 and 24 after surgery, as previously 
reported [Bura et al. 2013;Strekalova et al. 2006]. During the 4 days preceding surgery, two 
bottles of water, one with 2% sucrose and the other without, were placed in the cage. Every day 
the position of the bottles was exchanged, and the consumption from each bottle measured. On 
the day of the test, the two bottles were placed again in the cage and the consumption from each 
recorded after a 24h interval. The preference for sucrose was calculated as the relative amount of 
water with sucrose versus total liquid (water with and without sucrose) consumed by the mice. 
 
Tail suspension test (TST): This test was performed on day 12 after surgery, as previously 
reported [Steru et al. 1985;Aso et al. 2008]. Mice were suspended 50 cm above a solid surface 
by the use of adhesive tape applied to the tail (3/4 of the distance from the base of mouse tail). 
During a six minutes interval, the total time of immobility was recorded.  Long periods of 
immobility are characteristic of a depressive-like state; an alternative test is the forced swimming 
test, which was also applied at a different time point (see below). 
 
Forced swimming test (FST): This test was performed on day 20 after surgery, as previously 
reported [Filliol et al. 2000;Porsolt et al. 1977]. The mouse was placed in a plastic cylinder 
containing warm water (27-28 °C), deep enough to prevent touching the bottom of the cylinder 
and forcing the mouse to swim. The trial lasted 6 minutes and the total time of immobility after 
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minute 2:00 was recorded. Time of immobility was defined as the time that the animal stopped 
swimming and only used minimal movements to keep the head above the water. 
 
Black and white test: This test was performed on day 6 after surgery, as reported [Bura et al. 
2010;Crawley and Goodwin 1980]. It measures the conflict between the natural tendency of 
rodents to explore new environments and the tendency to avoid brightly illuminated areas. The 
box consisted of two compartments (20 cm wide × 20 cm long × 30 cm high) connected by a 
6 cm wide by 6 cm high tunnel. One compartment was painted black and maintained at 10 lux, 
while the other compartment was painted white, brightly illuminated (500 lux), and subdivided 
into three sections (distal, medial and proximal), based on the distance from the tunnel. The floor 
of both compartments was subdivided into squares (5x5 cm) to measure the locomotor activity. 
At the start of the session, mice were placed in the black compartment, head facing a corner. The 
latency of first entry into the white compartment and section reached in each entry, together with 
time spent, squares crossed, and number of entries into both compartments were recorded and 
used to evaluate anxiety. 
 
Elevated plus maze test: This test was performed on day 14 after surgery, as reported [Handley 
and Mithani 1984;Llorente-Berzal et al. 2013]. The test is based on the same principle as the 
black and white test, and measures the conflict between the natural tendency of mice to avoid an 
illuminated and elevated surface, and the natural tendency to explore new environments. It 
consisted of a plastic black cross with arms 40 cm long and 6 cm wide placed 50 cm above the 
floor. Two opposite arms were surrounded by walls (15 cm high, closed arms, 10 lux), while the 
two other arms were devoid of such walls (open arms, 200 lux). The four arms were connected 
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by a central platform. At the start of the session, the mouse was placed at the end of a closed arm 
facing the wall. During the 5-minute trial, the number of entries and the time spent in each arm 
were recorded. Anxiety was assessed as both the time spent avoiding the open arms and the 
number of entries into them. 
 
Resident-intruder test: This test, performed on days 3, 10, 18 and 25 after surgery, evaluates 
aggressive behavior in rodents, as reported [Konig et al. 1996;Burokas et al. 2012]. Resident 
mice were housed individually for at least 10 days before the test. Intruder animals of similar age 
and weight were housed five per cage. Each session consisted of putting together resident and 
intruder mice for a period of 4 minutes, measuring the latency of the first aggressive event and 
frequency of events.  
 
Locomotor activity: This test was performed on days 3, 10, 18 and 25 after surgery. Animals 
were assessed in locomotor activity boxes (9×20×11 cm; Imetronic, Passac, France), equipped 
with 2 rows of photocell detectors, and placed in a low-luminosity environment (20–25 lux), as 
previously described [Caille et al. 1999;Berrendero et al. 2005]. The mouse locomotor activity 
was recorded for 10 minutes as horizontal activity and vertical activity. 
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Legends to supplemental figures 
 
Supplemental Figure 1: Quantification of human IgG present in mice cerebral cortex 
Quantification of the intensity of immunolabeling of human IgG present in frontal cortex of mice 
infused with patients’ CSF (grey columns) or control CSF (white columns) sacrificed at the 
indicated time points. The change over time of the amount of patients’ IgG detected in frontal 
cortex is similar to that demonstrated in hippocampus (see Figure 4 C: progressive increase until 
day 18 followed by a wash out period). Note that despite the similarity in the dynamics of 
patient’s IgG detection, in all time points the amount of patients’ IgG in frontal cortex was 
substantially less than that found in hippocampus (5% versus 100%) 
Mean intensity of immunostaining of patients’ IgG detected in hippocampus in the group with 
the highest value (animals infused with patients’ CSF examined at day 18) was defined as 100%. 
All data are presented as mean ± s.e.m.  For each time point 5 animals infused with patients’ 
CSF and 5 with control CSF were examined. Significance of treatment effect was assessed by 
two-way ANOVA with an α-error of 0.05 (*) and post-hoc testing with Sidak-Holm adjustment 
($). ***, $$$ P<0.001; $, P<0.05.  
 
Supplemental Figure 2: Abscence of brain-bound NMDAR-specific IgG in mice infused 
with CSF from NMDAR antibody negative patients (control)  
HEK293 cells expressing the GluN1 subunit of the NMDAR immunolabeled with acid-extracted 
IgG fractions (top row) from hippocampus of mice infused with control CSF and sacrificed on 
the indicated days. No reactivity is observed. The second row shows the reactivity with a 
monoclonal GluN1 antibody, and the third row the co-localization of immunolabeling. Scale 
bars=10µm.   
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Supplemental Table 1: Statistical analysis of cognitive and memory tests  
    2way ANOVA analysis       Post-hoc analysis     
  Test Variable 
Source of 
variation 
Uncorrected 
P-value 
F-value Day 
Mean 
patients' 
CSF 
Mean 
control 
CSF 
Difference 
Multiplicity-
adjusted P-
value
&
 
M
e
m
o
ry
 
Novel object 
recognition - 
open field 
Novel object 
recognition 
index 
Time <0.001 9.96 3 0.25 0.40 -0.15 0.066 
Treatment <0.001 67.5 10 0.08 0.52 -0.44 <0.001 
Interaction <0.001 9.45 
18 -0.03 0.46 -0.49 <0.001 
25 0.45 0.51 -0.06 0.40 
Total time of 
exploration 
(Internal 
control) 
Time 0.003 5.48 
  
Treatment 0.37 0.86 
       
Interaction 0.18 1.76 
       
Novel object 
recognition - 
V-maze 
Novel object 
recognition 
index 
Time <0.001 12.6 3 0.35 0.41 -0.056 0.066 
Treatment <0.001 24.2 10 0.15 0.46 -0.31 <0.001 
Interaction <0.001 11.3 
18 0.06 0.26 -0.40 <0.001 
25 0.47 0.50 -0.031 0.40 
Total time of 
exploration 
(Internal 
control) 
Time <0.001 14.8 
       
Treatment 0.39 0.76 
       
Interaction 0.37 1.07           
  
A
n
h
e
d
o
n
ia
 
Sucrose 
preference 
test 
Percentage 
of sucrose 
preference 
Time 0.30 1.22 
-4 to 
0 
85.60 86.92 -1.33 0.89 
Treatment 0.10 2.87 10 74.64 87.66 -13.02 0.016 
Interaction 0.068 2.82 24 85.40 83.47 1.93 0.89 
Total fluid 
consumption 
(Internal 
control) 
Time <0.001 10.1   
      
Treatment 0.50 0.46   
      
Interaction 0.87 0.14   
      
L
o
c
o
m
o
ti
o
n
 
Locomotor 
activity test 
Horizontal 
Activity 
Time <0.001 14.6 
       
Treatment 0.40 0.73 
       
Interaction 0.85 0.34 
       
Vertical 
Activity 
Time <0.001 39.0 
       
Treatment 0.98 0.001 
       
Interaction 0.80 0.41 
       
A
g
g
re
s
s
iv
e
n
e
s
s
 Resident-
instruder test 
Frequency 
Time <0.001 7.08 
       
Treatment 0.16 2.04 
       
Interaction 0.36 1.07 
       
Latency of 
aggressive 
events 
Time 0.46 0.85 
       
Treatment 0.29 1.14 
       
Interaction 0.98 0.068 
       
  Unpaired t-test / Mann Whitney-U test 
  Test, Day Variable 
mean patients' CSF              
(95% CI) 
mean control CSF             
(95% CI) 
Uncorrected 
P-value 
D
e
p
re
s
-
s
io
n
 Tail suspension test 
day 12 
Time of immobility 169.2 (136.2-179.8)* 192.4 (165.8-208.7)* 0,017* 
Forced swimming test 
day 20 
Time of immobility 93.8 (72.5-115) 83.1 (58.0-108) 0.50  
A
n
x
ie
ty
 Black and white test 
day 6 
Latency 67.8 (21.1-114) 29.2 (8.41-50.1) 0.25 
% Time in white box 12.4 (6.58-18.3) 14.9 (9.99-19.7) 0.19 
Entries in white box 6.39 (3.77-9.01) 7.00 (5.00-9.00) 0.70 
Entries in distal section 2.94 (1.46-4.43) 3.35 (2.20-4.50) 0.46 
Elevated plus maze test 
day 14 
% Time in open arms 6.27 (2.18-10.4) 6.75 (4.12-9.38) 0.15 
Entries in open arms 5.39 (2.51-8.26) 5.80 (4.24-7.36) 0.79 
 
In the 2-way ANOVA analysis a p-value of 0.05 is considered significant for the treatment effect. An 
interaction p-value < 0.10 is considered a sign of different treatment effects at different time points, 
warranting post-hoc analysis. Significant results for treatment effect or interaction of treatment and time 
are shown in bold. * Median, IQR and result of significance testing using Mann Whitney-U test indicated 
because of non-normality. & Multiplicity-adjusted P-value using Sidak-Holm post-hoc procedure. 
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Supplemental Table 2: Statistical analysis of human IgG and receptor studies  
  
2way ANOVA analysis 
    
Post-hoc analysis 
Test Variable 
Source of 
variation 
P-value F-value Day 
Mean 
patients' 
CSF 
Mean 
control 
CSF 
Differ-
ence 
Multiplicity-
adjusted P-
value 
&
 
Immuno-
histo-
chemistry 
(Figure 4) 
Human IgG intensity in 
hippocampus – 
Percent of patients’ 
CSF treated animals 
(100%) 
Time 0.0005 6.23 3 33.6 33.3 0.28 0.98 
Treatment <0.0001 24.7 
10 49.9 31.4 18.5 0.42 
18 100.0 24.0 76.0 <0.0001 
Interaction 0.003 4.89 
25 50.7 16.4 34.4 0.048 
46 25.0 8.84 16.1 0.42 
Immuno-
fluores-
cence 
(Figure 4) 
Human IgG intensity in 
hippocampus - 
Percent of patients’ 
CSF treated animals 
(100%) 
Region 0.93 0.077 CA1 100.0 16.0 84.1 <0.0001 
Treatment <0.0001 109.2 CA3 100.0 8.38 91.6 <0.0001 
Interaction 0.93 0.077 DG 100.0 14.4 85.6 <0.0001 
Confocal 
cluster 
density 
(Figure 6) 
NMDAR - Percent of 
control CSF treated 
animals (100%) 
Time 0.032 3.30 13 66.2 100.0 33.8 0.004 
Treatment <0.0001 51.8 18 43.4 100.0 56.6 <0.0001 
Interaction 0.032 3.30 26 76.8 100.0 23.2 0.054 
      46 80.8 100.0 19.2 0.18 
Synaptic NMDAR  - 
Percent of control CSF 
treated animals 
(100%) 
Time 0.086 2.40 13 65.0 100.0 35.0 0.33 
Treatment 0.039 2.40 18 44.9 100.0 55.1 0.044 
Interaction 0.086 4.60 26 118.5 100.0 -18.5 0.82 
      46 84.8 100.0 15.3 0.92 
PSD95  - Percent of 
control CSF treated 
animals (100%) 
Time 0.73 1.13 
    
Treatment 0.97 0.028 
    
Interaction 0.73 1.13           
Total 
protein - 
Immuno-
blot     
(Figure 7) 
NMDAR GluN1 - 
Percent of control CSF 
treated animals 
(100%) 
Time 0.022 3.63 13 65.6 100.0 34.4 0.0082 
Treatment 0.0008 13.2 18 63.7 100.0 36.3 0.0067 
Interaction 0.022 3.63 26 80.3 100.0 19.7 0.19 
  
  
46 110.0 100.0 -9.54 0.40 
PSD95 - Percent of 
control CSF treated 
animals (100%) 
Time 0.91 0.18           
Treatment 0.43 0.64   
   
Interaction 0.91 0.18   
   
Kruskal-Wallis analysis Post-hoc analysis 
Test Variable P-value Test statistic 
Pairwise 
Day 
Mean 
rank 1 
Mean 
rank 2 
Differ-
ence 
P
@
 
IgG 
extraction 
hippo-
campus 
(Figure 5) 
NMDAR antibody titer 0.0004 20.6 
46 vs. 5 3 8.38 -5.38 1.0 
46 vs. 13 3 20.5 -17.5 0.0004 
46 vs. 18 3 18.1 -15.1 0.0031 
46 vs. 26 3 11.7 -8.7 0.24 
13 vs. 18 18.1 20.5 -2.4 1.0 
Unpaired t-test 
Test Variable mean patients' CSF (95% CI)   mean control CSF (95% CI) 
Uncorrected 
P-value 
Confocal 
cluster 
density 
(Figure 6) 
AMPAR - Percent of control CSF 
treated animals (100%) 
90.9 (84.6-97.2) 100.0 (86.6-113.5) 0.14 
Synaptic AMPAR - Percent of control 
CSF treated animals (100%) 
94.8 (71.6-118.0) 100.0 (77.8-122.2) 0.66 
PSD95  - Percent of control CSF 
treated animals (100%) 
93.4 (82.4-104.4) 100.0 (86.9-113.1) 0.33 
Immuno-
blot      
(Figure 7) 
AMPAR - Percent of control CSF 
treated animals (100%) - day 18 
106.5 (76.4-136.5) 100.0 (58.5-151.5) 0.75 
 
In the 2-way ANOVA analysis a p-value of 0.05 is considered significant for the treatment effect. An 
interaction p-value < 0.10 is considered a sign of different treatment effects at different time points, 
warranting post-hoc analysis. Significant results for treatment effect or interaction of treatment and time 
are shown in bold. &Multiplicity-adjusted P-value using Sidak-Holm post-hoc procedure. @Multiplicity-
adjusted P-value by Dunn's post-hoc procedure.  
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Supplemental Figure 1: Quantification of human IgG present in mice cerebral cortex  
Quantification of the intensity of immunolabeling of human IgG present in frontal cortex of mice infused with 
patients’ CSF (grey columns) or control CSF (white columns) sacrificed at the indicated time points. The 
change over time of the amount of patients’ IgG detected in frontal cortex is similar to that demonstrated in 
hippocampus (see Figure 4 C: progressive increase until day 18 followed by a wash out period). Note that 
despite the similarity in the dynamics of patient’s IgG detection, in all time points the amount of patients’ 
IgG in frontal cortex was substantially less than that found in hippocampus (5% versus 100%)  
Mean intensity of immunostaining of patients’ IgG detected in hippocampus in the group with the highest 
value (animals infused with patients’ CSF examined at day 18) was defined as 100%. All data are presented 
as mean ± s.e.m.  For each time point 5 animals infused with patients’ CSF and 5 with control CSF were 
examined. Significance of treatment effect was assessed by two-way ANOVA with an α-error of 0.05 (*) and 
post-hoc testing with Sidak-Holm adjustment ($). $$$ P<0.001; $ P<0.05.  
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Supplemental Figure 2: Abscence of brain-bound NMDAR-specific IgG in mice infused with CSF from NMDAR 
antibody negative patients (control)  
HEK293 cells expressing the GluN1 subunit of the NMDAR immunolabeled with acid-extracted IgG fractions 
(top row) from hippocampus of mice infused with control CSF and sacrificed on the indicated days. No 
reactivity is observed. The second row shows the reactivity with a monoclonal GluN1 antibody, and the third 
row the co-localization of immunolabeling. Scale bars=10µm.  
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